GenapSys develops a scalable semiconductor-based electronic sequencing platform that leverages a proprietary electrical microfluidic sequencing chip. The system uses a scalable number of detectors to support a wide range of applications. The company raised $70M in Series D equity financing and intends to use the funds to continue advancing its next-generation sequencing (NGS) platform. GenapSys products are provided for Research Use Only and are not for use in diagnostic procedures. The platform is positioned to empower both academic and clinical research applications and to advance universal access to genomic information. Leadership includes CEO Jason Myers, Ph.D., and Founder and Chairman Dr. Hesaam Esfandyarpour; the company is based in Redwood City, California. GenapSys develops a compact, accurate gene sequencer designed for rapid pathogen sequencing and deployment outside traditional labs. The device can run off a standard power source and is small enough to fit in the back of a truck or be deployed at hospitals, airports, and public transportation hubs for quick virus-sample results. Led by founder and CEO Dr. Hesaam Esfanyarpour and based in Redwood City, the company has launched its sequencer across the Asia-Pacific region, including Korea, Singapore, Japan and the Chinese gene-sequencing market. GenapSys has signed more than 25 distributorship deals as part of its international expansion. The company says it is actively seeking partnerships with local health agencies and researchers to support outbreak control and to broaden access to sequencing insights. Financially, GenapSys raised up to $75M in new financing provided by Oxford Finance to help scale its global presence. GenapSys develops a direct electronic sequencing system that leverages a proprietary electrical microfluidic sequencing chip with a scalable detector array. The platform supports applications from targeted amplicon sequencing to genome-scale data collection and has been tested across leading genomics labs nationwide. The GenapSys Sequencer is available for order in the U.S., with global sales planned to begin in early 2020. Stated application areas include genomics discovery, biomedical research, healthcare, diagnostics, and agriculture. The company completed a $90M Series C and has raised $166M in total funding to date. Management plans to use the proceeds to commercialize the sequencer, grow the team, and fund continued innovation; the company also added veteran biotech executives to its board and maintains a scientific advisory board of prominent genetics researchers. GenapSys is a Redwood City, Calif.-based provider of next-generation sequencing systems. Led by founder and CEO Dr. Hesaam Esfandyarpour, the company has created and is producing a Genomic Testing system that integrates advanced fluidics and analytical capabilities. Its first product, the GENIUS™ 110 System, aims to enable customers to replace sample preparation and sequencing bottlenecks with a streamlined workflow for next-generation sequencing. The company closed a $37M Series B to support continued development of its platform and commercialization. Backers in the round included existing investors Decheng Capital and IPV Capital as well as new investors such as Yuri Milner and the Stanford StartX Fund. GenapSys intends to use the funds to continue to develop its platform through commercialization. Genapsys builds the Genius system-on-a-chip sequencing technology and a $3,000 device designed to replace equipment that can cost more than $500,000. The platform is marketed as significantly cheaper than competitors and to offer dramatically faster turnaround times. The company has raised funding to advance the technology, reporting $8.5 million of a $13.5 million round in an SEC filing. In September it also received a $4 million grant from the National Human Genome Research Institute to improve gene-sequencing technology. Genapsys was founded in 2006 by Dr. Hesaam Esfandyarpour, is based in Redwood City, California, and comes out of Stanford’s StartX program. The company’s current financing and grant support signal ongoing development and commercialization efforts for its chip-based sequencer.

Total raised

$281M

Funding rounds

5

Latest round

Series D

Latest activity

May 2021